Webinar: Wednesday, 12 June 2024, 7PM

Parafengen IV: Unlocking synergy- fusing the power of paracetamol & Ibuprofen the ultimate blend for pain relief 

Join Medical Chronicle for a free, one-hour, webinar on: Parafengen IV: Unlocking synergy-fusing the power of paracetamol & Ibuprofen the ultimate blend for pain relief. The webinar is sponsored by Acino and will be presented by Dr Hartley Atkinson and Erni Welch.

Presented by
Conrad Strydom

Conrad Strydom

  • Editor: Medical Academic
Dr Erni Welch

Dr Erni Welch

  • Anaesthetist
Dr Erni Welch obtained his MBBCh at the University of the Witwatersrand. He then specialised in Anaesthesiology on the WITS Anaesthesia circuit whereafter he took up a consultant post at Baragwanath Hospital. In 2003 he joined the Dunkeld Practice. Erni has been a feature of academic anaesthesia in South Africa and Johannesburg for many years. He has been a convenor examiner for the Fellowship Part 1 exams, and has been intimately involved in Part 1 teaching on the WITS Circuit and at various Refresher Courses. He is the chair of the Anaesthetic Foundation which runs academic meetings in Johannesburg yearly. He co-authored Applied Pharmacology in Anaesthesiology and Critical Care with Prof Analee Milner, which has become a staple text of Pharmacology. He is passionate about pharmacology and Intravenous anaesthesia techniques and has lectured widely on these topics.
Dr Hartley Atkinson

Dr Hartley Atkinson

  • Pharmacologist
Dr Hartley Atkinson is a Pharmacologist and registered pharmacist who has a Masters of Pharmaceutical Chemistry with distinction and Doctorate in Pharmacology from Otago University, New Zealand. He has published over 30 research papers [including the world leading New England Journal of Medicine] and 2book chapters. Hartley was previously Medical Director for Roche New Zealand and left to found, with his wife Marree, AFT Pharmaceuticals 25 years ago which is now listed on the Australian and New Zealand stock exchanges. AFT Pharma undertakes extensive drug development work to repurpose existing drugs for the treatment of various medical conditions such as Maxigesic which avoids the need for opioids. Other examples of R&D projects include treatments for Burning Mouth Syndrome, Port Wine Stains, Strawberry Birthmarks, Keloid Scars, Vulva Lichen Sclerosis and Antibiotic Resistant Eye Infections. Its R&D based products are presently sold in over 70 countries around the globe with regulatory approvals across EU and USA.

437 professionals have already registered.

Days
:
Hours
:
Minutes
:
Seconds

Webinar Registration

By registering for this webinar, you agree to our Terms & Conditions.

New Media, a division of Media24 (PTY) Ltd., abides to all data and privacy requirements. To find out more about our Privacy Policy you can find it here: www.media24.com/group-privacy-portal.

Please Note: The names, surnames, email addresses and duration of attendance of all webinar participants will be shared for statistical purposes only, with the sponsor of this webinar. No delegate will be contacted by the sponsor with marketing or sales offers, and your information will not be shared with any third-parties.

Should you wish to receive further information on the webinar topic from our sponsor, please opt in above.

Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za